Opławski Marcin, Dziobek Konrad, Adwent Iwona, Dąbruś Dariusz, Grabarek Beniamin, Zmarzły Nikola, Plewka Andrzej, Boroń Dariusz
Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Sosnowiec, Poland.
Department of Gynecology and Obstetrics with Gynecologic Oncology, Ludwik Rydygier Memorial Specialist Hospital, Krakow, Poland.
Curr Pharm Biotechnol. 2018;19(12):990-995. doi: 10.2174/1389201020666181127152605.
Endoglin is a marker of active, proliferating endothelial cells of blood vessels. In many cancers, it is present in both peripheral vessels and vessels located inside the tumor. Endoglin is more specific and sensitive compared to other tumor angiogenesis markers. It is suggested that endoglin can be considered a reliable marker of disease outcome.
The aim of the study was to assess the expression of endoglin and to determine its potential usefulness as a complementary molecular marker of endometrial cancer.
The study included 60 women who underwent hysterectomy: 45 with endometrioid endometrial cancer (study group) and 15 without neoplastic changes (control group). The study group was further divided according to the degree of histological differentiation: G1, 17; G2, 15; and G3, 13. The expression of endoglin was determined immunohistochemically with mouse anti-Endoglin monoclonal antibody. The obtained reactions were evaluated using light microscopy.
Analysis of endoglin expression in endothelium showed that it reached 145% of the control. In G2, we observed that the endoglin level decreased and was similar to the control, while in G3 it increased and was even higher than in G1. In cancer cells, endoglin expression increased with the grade of endometrial cancer.
Endoglin can be considered a valuable complementary molecular marker, allowing to visualize the advancement of the cancer process, including endometrial cancer.
内皮糖蛋白是活跃的、增殖的血管内皮细胞的标志物。在许多癌症中，它存在于外周血管和肿瘤内部的血管中。与其他肿瘤血管生成标志物相比，内皮糖蛋白更具特异性和敏感性。有人认为内皮糖蛋白可被视为疾病预后的可靠标志物。
本研究旨在评估内皮糖蛋白的表达，并确定其作为子宫内膜癌补充分子标志物的潜在用途。
该研究纳入了60例行子宫切除术的女性：45例患有子宫内膜样腺癌（研究组），15例无肿瘤性改变（对照组）。研究组根据组织学分化程度进一步分为：G1组17例；G2组15例；G3组13例。采用小鼠抗内皮糖蛋白单克隆抗体通过免疫组织化学法测定内皮糖蛋白的表达。使用光学显微镜对获得的反应进行评估。
对内皮细胞中内皮糖蛋白表达的分析表明，其达到对照组的145%。在G2组中，我们观察到内皮糖蛋白水平下降且与对照组相似，而在G3组中其水平升高且甚至高于G1组。在癌细胞中，内皮糖蛋白表达随子宫内膜癌分级增加而升高。
内皮糖蛋白可被视为一种有价值的补充分子标志物，有助于直观显示癌症进展过程，包括子宫内膜癌。
